Synthetic Messenger RNA as a Tool for Gene Therapy

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Human Gene Therapy

• Publication date

  2006-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/hum.2006.17.1027PMID 17007566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef.

  2006cited by this paper
• Generation of tumor-specific T-cell therapies.

  2006cited by this paper
• Viral gene therapy strategies: from basic science to clinical application

  2006cited by this paper
• Optimized transfection of mRNA transcribed from a d(A/T)100 tail-containing vector.

  2005cited by this paper
• Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

  2005cited by this paper
• Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

  2004cited by this paper
• The molecular mechanics of eukaryotic translation.

  2003cited by this paper
• Preventing nondesired RNA-primed RNA extension catalyzed by T7 RNA polymerase.

  2003cited by this paper
• mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT).

  2002cited by this paper
• Gene therapy. Safer and virus-free?

  2001cited by this paper
• Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG.

  2001cited by this paper
• Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells.

  2001cited by this paper
• Molecular mechanisms of translation initiation in eukaryotes

  2001cited by this paper
• Safer and Virus-Free?

  2001cited by this paper
• Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.

  2000cited by this paper
• Apoptosis induced by DNA uptake limits transfection efficiency.

  1999cited by this paper
• Efficient coupled transcription/translation from PCR template by a hollow-fiber membrane bioreactor.

  1999cited by this paper
• Basic Techniques in Mammalian Cell Tissue Culture

  1998cited by this paper
• Transcription of RNA templates by T7 RNA polymerase.

  1998cited by this paper
• In vitro transcription of a poly(dA) x poly(dT)-containing sequence is inhibited by interaction between the template and its transcripts.

  1996cited by this paper
• A common function for mRNA 5' and 3' ends in translation initiation in yeast.

  1995cited by this paper
• Ribosomal Decoding Processes at Codons in the A or P Sites Depend Differently on 2′-OH Groups (*)

  1995cited by this paper
• Self-coded 3′-Extension of Run-off Transcripts Produces Aberrant Products during in Vitro Transcription with T7 RNA Polymerase (*)

  1995cited by this paper
• Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

  1995cited by this paper
• Instability of plasmid DNA maintenance caused by transcription of poly(dT)-containing sequences in Escherichia coli.

  1994cited by this paper
• Instability of plasmid DNA maintenance caused by transcription of poly(dT)-containing sequences in Escherichia coli.

  1994cited by this paper
• Termination and slippage by bacteriophage T7 RNA polymerase.

  1993cited by this paper
• A novel transcription property of SP6 and T7 RNA polymerases: dependence on template structure.

  1985cited by this paper
• Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements.

  1983cited by this paper
• The Role of the poly(A) sequence in mammalian messenger RNA.

  1981cited by this paper

• Advances and Strategies in Enhancing mRNA Cancer Vaccines

  2025cites this paper
• Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases

  2025cites this paper
• Rational design of lipid nanoparticles for enabling gene therapies

  2025cites this paper
• A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines.

  2024cites this paper
• Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR–T) cell immunotherapy

  2024cites this paper
• Augmenting the landscape of chimeric antigen receptor T-cell therapy

  2024cites this paper
• Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials

  2024cites this paper
• RNA therapies for musculoskeletal conditions.

  2024cites this paper
• Non-viral vectors for chimeric antigen receptor immunotherapy

  2024cites this paper
• Non-viral delivery of RNA for therapeutic T cell engineering.

  2024cites this paper
• Poly(A) tale: From A to A; RNA polyadenylation in prokaryotes and eukaryotes

  2024cites this paper
• Future prospects in mRNA vaccine development

  2023cites this paper
• mRNA‐based chimeric antigen receptor T cell therapy: Basic principles, recent advances and future directions

  2023cites this paper
• Ionizable lipids penetrate phospholipid bilayers with high phase transition temperatures: perspectives from free energy calculations.

  2023cites this paper
• mRNA-based cancer therapeutics

  2023cites this paper
• Electroactive nanoinjection platform for intracellular delivery and gene silencing

  2023cites this paper
• Comprehensive studies on building a scalable downstream process for mRNAs to enable mRNA therapeutics

  2022cites this paper
• Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases.

  2022cites this paper
• mRNA vaccines: the most recent clinical applications of synthetic mRNA

  2022cites this paper
• The Pivotal Role of Chemical Modifications in mRNA Therapeutics

  2022cites this paper
• Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression.

  2022cites this paper
• mRNA therapeutics in cancer immunotherapy

  2021influential citation
• Synthetic modified messenger RNA for therapeutic applications

  2021cites this paper
• mRNA Delivery by a pH-Responsive DNA Nano-Hydrogel.

  2021cites this paper
• Chemically modified mRNA nucleofection of primary human T cells.

  2020cites this paper
• In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update

  2020cites this paper
• Ionizable Lipid Nanoparticle Mediated mRNA Delivery for Human CAR T Cell Engineering.

  2020cites this paper
• Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives

  2020cites this paper
• RNA-electroporated T cells for cancer immunotherapy

  2020cites this paper
• A versatile flow-based assay for immunocyte-mediated cytotoxicity.

  2019cites this paper
• Enhancing Stability of Destabilized Green Fluorescent Protein Using Chimeric mRNA Containing Human Beta-Globin 5′ and 3′ Untranslated Regions

  2019cites this paper
• The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy.

  2019influential citation
• Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts.

  2018cites this paper
• The siRNA‐mediated downregulation of PD‐1 alone or simultaneously with CTLA‐4 shows enhanced in vitro CAR‐T‐cell functionality for further clinical development towards the potential use in immunotherapy of melanoma

  2018cites this paper
• Biomedical applications of mRNA nanomedicine

  2018cites this paper
• The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma

  2018cites this paper
• Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA–Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy

  2018cites this paper
• Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine.

  2018cites this paper
• Steering CAR T cells to distinguish friend from foe

  2017cites this paper
• Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences.

  2016cites this paper
• Gene Manipulation of Human Embryonic Stem Cells by In Vitro-Synthesized mRNA for Gene Therapy.

  2015cites this paper
• Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone

  2015cites this paper
• Methods of Transfection with Messenger RNA Gene Vectors

  2015cites this paper
• Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond

  2015cites this paper
• Récepteurs d'antigènes chimères (car) utilisés dans un traitement et méthodes de fabrication associées

  2015cites this paper
• mRNA transcript therapy

  2015cites this paper
• Gene Transfer into T Cells

  2014cites this paper
• mRNA-based therapeutics — developing a new class of drugs

  2014cites this paper
• 4-1BB Chimeric Antigen Receptors

  2014cites this paper
• CAR-MODIFIED T CELLS CAPABLE OF DISTINGUISHING NORMAL CELLS FROM MALIGNANT CELLS

  2014influential citation
• Natural killer cell reprogramming with chimeric immune receptors.

  2013cites this paper
• Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy.

  2013cites this paper
• Steve Ramirez Creating a False Memory in the Hippocampus

  2013cites this paper
• Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection.

  2013cites this paper
• Large volume flow electroporation of mRNA: clinical scale process.

  2013cites this paper
• A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus

  2013cites this paper
• METHODS: ORIGINAL ARTICLE A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus

  2013cites this paper
• Creating a False Memory in the Hippocampus

  2013cites this paper
• The two hit hypothesis: an improved method for siRNA-mediated gene silencing in stimulated primary human T cells.

  2013cites this paper
• Feeder-free reprogramming of human fibroblasts with messenger RNA.

  2013cites this paper
• Cell engineering with synthetic messenger RNA.

  2013cites this paper
• Targeted immunotherapy of cancer with CAR T cells: achievements and challenges

  2012cites this paper
• A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies.

  2012cites this paper
• mRNA as a versatile tool for exogenous protein expression.

  2012cites this paper
• Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics

  2011cites this paper
• High transfection efficiency of porcine peripheral blood T cells via nucleofection.

  2011cites this paper
• Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo

  2010cites this paper
• Nucleoside Modifications Suppress RNA Activation of Cytoplasmic RNA Sensors

  2010cites this paper
• Delivery of messenger RNA using poly(ethylene imine)-poly(ethylene glycol)-copolymer blends for polyplex formation: biophysical characterization and in vitro transfection properties.

  2010cites this paper
• Non-MHC-dependent redirected T cells against tumor cells.

  2010cites this paper
• Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.

  2010cites this paper
• Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method

  2010cites this paper
• Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

  2009cites this paper
• A fast and robust method to clone and functionally validate T-cell receptors.

  2009cites this paper
• Chimeric Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes

  2008influential citation
• Improving natural killer cells.

  2008cites this paper
• Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells.

  2007cites this paper